Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Breast Neoplasms 4 Multiple Myeloma 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia, Myeloid, Acute 2 Testicular Neoplasms 1 Testicular Germ Cell Tumor 1 Seminoma 1 Prostate Cancer Metastatic 1 Ovarian Neoplasms 1 Neutropenia 1 Neoplasms 1 Lymphoma, B-Cell 1 Hodgkin Disease 1 Endodermal Sinus Tumor 1 Central Nervous System Neoplasms 1 Castrate Resistant Prostate Cancer 1

Interventions

Cyclophosphamide 165 fludarabine phosphate 110 Peripheral Blood Stem Cell Transplantation 94 Mycophenolic Acid 88 Whole-Body Irradiation 81 Etoposide 81 Tacrolimus 73 Busulfan 68 Melphalan 67 Filgrastim 66 fludarabine 62 Radiotherapy 56 Doxorubicin 54 Cyclosporine 54 Rituximab 50 Brentuximab Vedotin 48 Antilymphocyte Serum 47 Granulocyte Colony-Stimulating Factor 42 Vinblastine 41 Methotrexate 38 Dacarbazine 37 Cytarabine 35 Gemcitabine 34 Nivolumab 30 Bleomycin 29 Carmustine 28 Vincristine 25 Prednisone 25 Sirolimus 24 Bendamustine Hydrochloride 23

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Hodgkin Disease × Lenograstim × Clear all

NCT01085058 2010-03-11

CU01

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2/3 Completed

LymphoidPlasma cell

Hodgkin Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡